SR One Capital Management’s enGene Therapeutics ENGN Stock Holding History

SR One Capital Management’s Portfolio ENGN Stock Details ENGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.29M	Hold	747,750	–	–	0.12%	15
2026 Q1	$5.09M	Hold	747,750	–	–	0.56%	13
2025 Q4	$6.75M	Hold	747,750	–	–	0.96%	11
2025 Q3	$5.11M	Hold	747,750	–	–	0.74%	12
2025 Q2	$2.72M	Hold	747,750	–	–	0.59%	13
2025 Q1	$3.35M	Hold	747,750	–	–	0.86%	12
2024 Q4	$4.97M	Hold	747,750	–	–	1.21%	10
2024 Q3	$4.94M	Buy	747,750 +247,750	+50%	+$1.84M	0.99%	10
2024 Q2	$4.71M	Buy	+500,000	New	+$6.41M	1.48%	8

Other funds holding ENGN

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

SR One Capital Management's ENGN Position: Q2 2026 in Review

SR One Capital Management held its enGene Therapeutics (ENGN) position steady in Q2 2026 at 747,750 shares worth $1.29M. The position accounts for 0.12% of the portfolio, ranked #15.

SR One Capital Management first reported a position in ENGN in Q2 2024 and has held it in 9 quarters since. The position peaked at $6.75M in Q4 2025. 60 funds tracked by Wall St. Rank hold ENGN as of Q2 2026.

SR One Capital Management held 747,750 shares of enGene Therapeutics worth $1.29M as of Q2 2026.
SR One Capital Management left its enGene Therapeutics share count unchanged in Q2 2026.
enGene Therapeutics made up 0.12% of SR One Capital Management's portfolio in Q2 2026, its #15 holding.
SR One Capital Management first reported a position in enGene Therapeutics in Q2 2024 and has held it in 9 quarters since.
SR One Capital Management's enGene Therapeutics position peaked at $6.75M in Q4 2025.
60 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2026.

Based on SR One Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.